Bill
HB 2871
Illinois agencies must develop and share evidence-based tardive dyskinesia screening guidelines and education for Medicaid patients on antipsychotics in state facilities and commun
Status summary
- Jurisdiction: Illinois (amends the Illinois Public Aid Code; new section 305 ILCS 5/5-5.09a).
- Introduced: February 6, 2025 (filed Feb 5–6, 2025).
- Sponsor (Illinois): Rep. Lindsey LaPointe.
- Most recent procedural note provided: Re-referred to Rules Committee (Rule 19(a)) on April 11, 2025.
- Note: The legislative file supplied also contains unrelated text from an Arizona appropriation bill concerning ibogaine research; this summary focuses only on the Illinois Medicaid/tardive dyskinesia provisions.
Purpose and intent
The bill directs Illinois’ health and human services agencies to create and distribute evidence-based, recommended screening guidelines and educational materials to improve identification and management of tardive dyskinesia (TD) among Medicaid beneficiaries who are prescribed antipsychotic medications in State-operated residential facilities and community-based settings.
Key provisions
- Requirement to develop recommended screening guidelines:
- The Department of Healthcare and Family Services (HFS), in collaboration with the Department of Human Services (DHS) and the Department of Public Health (DPH), must develop recommended screening guidelines for tardive dyskinesia for providers who serve Medicaid patients prescribed antipsychotics in State-operated residential facilities and community settings.
- The guidelines must be based on current, nationally accepted, evidence-based recommendations for assessment and treatment of TD.
- Guidelines must include structured assessment tools; these may be quantitative and/or qualitative.
Education and communication:
Statutory placement:
Who or what is affected
- Primary beneficiaries: Medicaid recipients prescribed antipsychotic medications who reside in State-operated residential facilities or receive services in community-based settings.
- Impacted providers: Physicians, psychiatrists and other clinicians serving those Medicaid patients—particularly providers working in state-run residential programs and community behavioral health providers.
- State agencies: Department of Healthcare and Family Services (lead, for medical assistance program), Department of Human Services, and Department of Public Health (collaborators).
- Professional associations: Statewide physician and psychiatrist associations will be consulted during development.
Implementation and likely effects
- The bill mandates development and dissemination of recommended guidelines and educational tools but does not itself require mandatory screening by providers (it establishes recommended, evidence-based guidance).
- No explicit funding, staffing, or implementation timeline is specified in the statute text as introduced; operational effects will depend on agency capacity and any future appropriations or rulemakings.
- Potential benefits: earlier detection and treatment of TD, increased provider awareness, more consistent use of structured assessments, and potential improvements in patient outcomes and medication management.
- Potential burdens: administrative/time costs for developing, adopting and training on new screening tools; providers may need training and operational adjustments to implement routine TD screening.
Legislative note
- The provision creates a statutory obligation for state agencies to produce recommended guidance and education, but additional steps (agency rulemaking, provider adoption, or funded implementation programs) would be required to make routine screening widespread and enforceable.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
